Massimiliano Fabbiani1, Simona Di Giambenedetto1, Eugenia Quiros-Roldan2, Alessandra Latini3, Vincenzo Vullo4, Andrea Antinori5, Antonella Castagna6, Giancarlo Orofino7, Daniela Francisci8, Elisabetta Grilli9, Giordanu Madeddu10, Pierfrancesco Grima11, Stefano Rusconi12, Barbara Del Pin13, Annalisa Mondi1, Alberto Borghetti1, Emanuele Focà2, Manuela Colafigli3, Andrea De Luca14, Roberto Cauda1. 1. Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy. 2. University Division of Infectious and Tropical Dis, University of Brescia, Brescia, Italy. 3. Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy. 4. Department of Infectious Diseases, "La Sapienza" University, Rome, Italy. 5. Department of Infectious Diseases, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy. 6. Department of Infectious and Tropical Diseases, San Raffaele Scientific Institute, Milan, Italy. 7. Infectious and Tropical Diseases Unit, Amedeo di Savoia Hospital, Turin, Italy. 8. Infectious Diseases Clinic, University of Perugia, Perugia, Italy. 9. Systemic Infections and Immunodeficiency Unit, National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS, Rome, Italy. 10. Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy. 11. Division of Infectious Diseases, "S. Caterina Novella" Hospital, Galatina, Italy. 12. Infectious Disease Unit, University of Milan, Milan, Italy. 13. Unit of Infectious Diseases, S.M. Annunziata Hospital, Florence, Italy. 14. Infectious Diseases Unit, Siena University Hospital, Siena, Italy.
Abstract
INTRODUCTION: We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART. METHODS:Subjects on ATV/r+2 NRTIs, without previous treatment failure (TF), with HIV-RNA <50copies/mL for >3 months and CD4>200 cells/mm(3) for >6 months were eligible. At baseline, patients were randomized to switch to ATV/r+3TC (arm one) or to maintain the original 3-drug regimen (arm two). PRIMARY ENDPOINT: proportion of patients free of TF at week 48. TF was defined as treatment modification for any reason, including virological failure (VF=two consecutive HIV-RNA>50 copies/mL or a single value >1000 copies/mL). Enrollment of 266 patients was planned. RESULTS: A total of 266 patients (78% males, median age 44 years, median CD4 603 cells/µL, 79% treated with a tenofovir-containing backbone) were enrolled. At the time of analysis, 24 weeks data were available for 84 and 87 patients in arm one and two, respectively. At baseline, subjects in the two arms did not differ for the main characteristics. At 24 weeks, at the intention to treat analysis the proportion of patients free of TF was 91.7% (95% CI 85.8-97.6) and 85.1% (95% CI 77.6-92.6) in arm one and two, respectively (difference +6.6%, 95% CI -2.9/+16.1). VF was observed in two patients randomized to arm one (one at baseline, before treatment simplification) and one to arm two without resistance mutations. Clinical and laboratory adverse events occurred at similar rates in the two arms. At week 24, patients in arm one showed a greater increase in CD4 (mean change +90 vs +10 cells/µL, p=0.007). A greater increase in total cholesterol (+18 vs -2 mg/dL, p<0.001), HDL (+4 vs +0 mg/dL, p=0.001) and LDL (+12 vs +0 mg/dL, p=0.001) was also observed in arm one without differences in other lipid parameters. Renal function showed a significant improvement in arm one (mean change in eGFR +5 vs -2 mL/min/1.73m(2) in arm two, p=0.001). No significant differences in bilirubin levels or other laboratory parameters were observed between the two arms. CONCLUSIONS: This interim analysis suggests a 24-weeks non-inferior efficacy of treatment simplification to ATV/rit+3TC as compared to continuation of ATV/rit +2 NRTI in virologically suppressed patients. Follow-up until 48-weeks is scheduled to confirm these data.
RCT Entities:
INTRODUCTION: We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART. METHODS: Subjects on ATV/r+2 NRTIs, without previous treatment failure (TF), with HIV-RNA <50copies/mL for >3 months and CD4>200 cells/mm(3) for >6 months were eligible. At baseline, patients were randomized to switch to ATV/r+3TC (arm one) or to maintain the original 3-drug regimen (arm two). PRIMARY ENDPOINT: proportion of patients free of TF at week 48. TF was defined as treatment modification for any reason, including virological failure (VF=two consecutive HIV-RNA>50 copies/mL or a single value >1000 copies/mL). Enrollment of 266 patients was planned. RESULTS: A total of 266 patients (78% males, median age 44 years, median CD4 603 cells/µL, 79% treated with a tenofovir-containing backbone) were enrolled. At the time of analysis, 24 weeks data were available for 84 and 87 patients in arm one and two, respectively. At baseline, subjects in the two arms did not differ for the main characteristics. At 24 weeks, at the intention to treat analysis the proportion of patients free of TF was 91.7% (95% CI 85.8-97.6) and 85.1% (95% CI 77.6-92.6) in arm one and two, respectively (difference +6.6%, 95% CI -2.9/+16.1). VF was observed in two patients randomized to arm one (one at baseline, before treatment simplification) and one to arm two without resistance mutations. Clinical and laboratory adverse events occurred at similar rates in the two arms. At week 24, patients in arm one showed a greater increase in CD4 (mean change +90 vs +10 cells/µL, p=0.007). A greater increase in total cholesterol (+18 vs -2 mg/dL, p<0.001), HDL (+4 vs +0 mg/dL, p=0.001) and LDL (+12 vs +0 mg/dL, p=0.001) was also observed in arm one without differences in other lipid parameters. Renal function showed a significant improvement in arm one (mean change in eGFR +5 vs -2 mL/min/1.73m(2) in arm two, p=0.001). No significant differences in bilirubin levels or other laboratory parameters were observed between the two arms. CONCLUSIONS: This interim analysis suggests a 24-weeks non-inferior efficacy of treatment simplification to ATV/rit+3TC as compared to continuation of ATV/rit +2 NRTI in virologically suppressed patients. Follow-up until 48-weeks is scheduled to confirm these data.
Authors: Pierre Gantner; Firouze Bani-Sadr; Rodolphe Garraffo; Pierre-Marie Roger; Michèle Treger; Thomas Jovelin; Pascal Pugliese; David Rey Journal: PLoS One Date: 2016-10-31 Impact factor: 3.240
Authors: Pedro Cahn; María José Rolón; María Inés Figueroa; Ana Gun; Patricia Patterson; Omar Sued Journal: J Int AIDS Soc Date: 2017-05-09 Impact factor: 5.396
Authors: Darrell H S Tan; Maria Jose Rolon; Maria Ines Figueroa; Omar Sued; Ana Gun; Rupert Kaul; Janet M Raboud; Leah Szadkowski; Mark W Hull; Sharon L Walmsley; Pedro Cahn Journal: PLoS One Date: 2019-09-06 Impact factor: 3.240